February and March 2018 – Ataxia

February and March 2018

February and March 2018

Positive results announced by Reata 

Positive results have been announced by the pharmaceutical company Reata, providing more support for the rationale to test their drug in neurodegenerative conditions such as Friedreich’s ataxia. Read the press release here. This drug is the same as the one currently in trials around the world including at the London Ataxia Centre. See here for more information about taking part.

Posted on 26/03/2018

New method for diagnosing ARSACS discovered at Specialist Ataxia Centre in London

An Ataxia UK-funded research study on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) has been published in the medical journal Brain. The study shows how a simple optical imaging technique can help provide an early diagnosis for ARSACS. Study lead Professor Paola Giunti (UCL Institute of Neurology, Head of the Ataxia Centre at UCL/UCLH and a BRC-funded Consultant) and colleague Dr Fion Bremner (also part of the Ataxia Centre), have used OCT to test a group of patients affected by ataxia to see if they could predict the genetic diagnosis causing ataxia in some patients. Read more about this study here.

Posted on 26/03/2018

New Options for Targeting Gene Mutation in Friedreich’s Ataxia Described in Nucleic Acid Therapeutics

Researchers have shown that a wide variety of synthetic antisense oligonucleotides with different chemical modifications can activate the frataxin gene, which contains a mutation that decreases its expression in the inherited neurologic disorder Friedreich’s ataxia (FA). This new finding, which demonstrates a broad range of flexible options for identifying novel compounds capable of increasing frataxin protein expression and alleviating the effects of FA, is published in Nucleic Acid Therapeutics. You can find the article here.

Posted 22/03/2018

Working with Industry – message from patients

Last Autumn, Findacure organised a day workshop to focus on the partnerships between patients’ groups and industry in the context of clinical research. Dr Julie Vallortigara, our research officer, attended this workshop and gave a talk about Ataxia UK’s view and experience of working with pharmaceutical companies for ataxia research. David Bennett-Orphan diseases/UK specialist wrote an article about this very informative day. You can find this article on rarebase website here

Posted 23/02/2018


Something went wrong. Please check your entries and try again.
fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email website@ataxia.org.uk
Scroll to Top